Medicare Coverage for Obesity & Weight Loss: 2025 Guide
Obesity affects more than 40% of American adults and is a major driver of diabetes, heart disease, sleep apnea, joint problems, and certain cancers. Medicare covers behavioral counseling and bariatric surgery for obesity — but has historically excluded weight loss medications. Two important 2024 approvals have begun to crack open that door, though with significant conditions attached.
Obesity & Weight Loss Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Obesity screening | Part B (preventive) | $0 — free | BMI measurement at primary care visits |
| Intensive behavioral therapy (IBT) for obesity | Part B (preventive) | $0 — free | Up to 22 sessions in first year; primary care setting |
| Bariatric surgery (gastric bypass, sleeve gastrectomy) | Part A or Part B | $1,676 deductible (inpatient) or 20% | BMI ≥35 with comorbidity, or BMI ≥40; at approved facility |
| Pre-operative bariatric evaluation | Part B | 20% after $257 deductible | Psych eval, nutritional counseling, sleep study |
| Post-bariatric nutritional support | Part B | 20% after deductible | Medical nutrition therapy after surgery |
| Semaglutide (Wegovy) — CVD indication | Part D | Up to $2,000 OOP cap | Covered for patients with obesity + established CVD; FDA approved March 2024 |
| Tirzepatide (Zepbound) — sleep apnea indication | Part D | Up to $2,000 OOP cap | Covered for moderate-severe OSA + obesity; FDA approved Dec 2024 |
| Semaglutide (Wegovy) — obesity only | Not covered | 100% out of pocket | Part D excluded from covering obesity-only drugs by law |
| Orlistat (Xenical, Alli) | Not covered | 100% out of pocket | Excluded as weight loss drug |
| Medical nutrition therapy (MNT) | Part B | 20% after deductible | Covered for diabetes and kidney disease; not obesity alone |
| Nutritional counseling (as part of AWV) | Part B (preventive) | $0 | Brief dietary counseling during Annual Wellness Visit |
| Diabetes Prevention Program (MDPP) | Part B (preventive) | $0 — free | For prediabetes; intensive lifestyle program; <3% utilization |
| Physical therapy (obesity-related conditions) | Part B | 20% after deductible | For joint pain, functional limitations related to obesity |
Intensive Behavioral Therapy: Free, Underused, Effective
Medicare Part B covers Intensive Behavioral Therapy (IBT) for obesity at $0 cost — no copay, no deductible — when provided in a primary care setting. Coverage includes:
- First year: 1 face-to-face visit per week for the first month, then 1 visit every 2 weeks for months 2–6, then monthly for months 7–12 — up to 22 sessions
- After year 1: If you've lost at least 6.6 lbs in the first 6 months, you can continue for an additional 12 months at monthly frequency
- Sessions focus on dietary change, increased physical activity, and behavioral strategies
- Must be provided in a primary care setting (primary care physician, NP, PA, or clinical nurse specialist)
This program is significantly underutilized. Ask your primary care provider about enrolling — it's one of the most comprehensive free weight management programs available through Medicare.
Bariatric Surgery: What Medicare Covers
Medicare covers bariatric surgery at Medicare-approved bariatric surgery centers when:
- BMI ≥35 with at least one obesity-related comorbidity (type 2 diabetes, hypertension, sleep apnea, heart disease, etc.), OR
- BMI ≥40 regardless of comorbidities
- Documentation of prior unsuccessful attempts at nonsurgical weight loss
- Psychological clearance
- Performed at a facility with a Medicare-approved bariatric surgery program
Covered procedures include:
- Roux-en-Y gastric bypass (RYGB)
- Laparoscopic adjustable gastric band (LAGB)
- Sleeve gastrectomy
- Biliopancreatic diversion with duodenal switch (BPD/DS)
The surgery is typically performed as an inpatient procedure (Part A, $1,676 deductible) or outpatient (Part B, 20% coinsurance). Medigap Plan G covers both cost-sharing amounts.
GLP-1 Medications: The Evolving Coverage Landscape
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) have revolutionized obesity treatment, producing 15–25% weight loss in clinical trials. However, Medicare Part D is prohibited by law from covering drugs approved solely for weight loss.
What IS Covered (2024–2025)
Semaglutide (Wegovy) for Cardiovascular Disease — Covered
In March 2024, the FDA approved semaglutide (Wegovy) to reduce cardiovascular events (heart attack, stroke) in adults with obesity or overweight AND established cardiovascular disease. Medicare Part D now covers Wegovy for this indication. If you have obesity + documented heart disease, stroke, or peripheral artery disease, your physician can prescribe Wegovy with Part D coverage. The $2,000 OOP cap applies.
Tirzepatide (Zepbound) for Sleep Apnea — Covered
In December 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity. Medicare Part D covers Zepbound for this indication. If you have obesity + diagnosed moderate-to-severe OSA, this is a covered option. Prior authorization is required by most Part D plans.
What is NOT Covered
- Wegovy, Zepbound, Saxenda, or any GLP-1 drug prescribed solely for weight loss/obesity — NOT covered
- OTC weight loss supplements — NOT covered
- Diet programs (Weight Watchers, Noom, etc.) — NOT covered
GLP-1 Drugs Covered for Diabetes (Ozempic, Mounjaro)
If you have type 2 diabetes, semaglutide (Ozempic) and tirzepatide (Mounjaro) are covered under Part D for diabetes management — and produce the same weight loss benefits as Wegovy/Zepbound. The diabetes indication is the coverage pathway for many Medicare patients who want GLP-1 benefits. See our Diabetes Coverage guide for details.
The Medicare Diabetes Prevention Program (MDPP)
For patients with prediabetes (not yet diabetes), Medicare covers the Medicare Diabetes Prevention Program at $0 cost. This structured lifestyle program:
- Targets 5–7% weight loss through diet and physical activity
- Delivers 16 core sessions in year 1 plus 6 monthly maintenance sessions in year 2
- Shown to reduce diabetes risk by 58% in the landmark DPP trial
- Available in-person and virtually through CDC-recognized programs
- Less than 3% of eligible Medicare beneficiaries have ever enrolled
If your blood sugar is elevated but not yet diabetic (A1C 5.7–6.4% or fasting glucose 100–125), ask your doctor about an MDPP referral.
Frequently Asked Questions
It depends on the indication. Wegovy (semaglutide) is covered under Part D if you have obesity or overweight AND established cardiovascular disease (heart attack, stroke, or peripheral artery disease) — this FDA indication was approved in March 2024. Ozempic (semaglutide) is covered under Part D for type 2 diabetes. Neither is covered for obesity alone under Original Medicare Part D, as federal law prohibits Part D from covering drugs approved solely for weight loss. Prior authorization is required for most GLP-1 approvals. The $2,000 Part D OOP cap applies when covered.
Yes. Medicare covers bariatric surgery (gastric bypass, sleeve gastrectomy, gastric banding) for patients with BMI ≥35 and an obesity-related comorbidity, or BMI ≥40 regardless of comorbidities. The surgery must be performed at a Medicare-approved bariatric surgery facility and requires documentation of prior weight loss attempts and psychological clearance. Most bariatric surgeries are performed inpatient (Part A, $1,676 deductible) though some sleeve gastrectomies may be outpatient (Part B, 20%). Medigap Plan G covers both.
Yes, at no cost. Medicare Part B covers Intensive Behavioral Therapy (IBT) for obesity in a primary care setting — up to 22 sessions in the first year at $0 cost to you. Sessions focus on dietary change, physical activity, and behavioral weight management strategies. You must have a BMI ≥30 to qualify. This benefit is dramatically underutilized — most Medicare beneficiaries who qualify have never accessed it. Ask your primary care physician to refer you for obesity counseling sessions.